Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Zevra Therapeutics (ZVRA) over the last 11 years, with Q3 2025 value amounting to $392000.0.

  • Zevra Therapeutics' Depreciation & Amortization (CF) fell 7575.76% to $392000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $5.3 million, marking a year-over-year decrease of 340.09%. This contributed to the annual value of $6.4 million for FY2024, which is 53508.95% up from last year.
  • Latest data reveals that Zevra Therapeutics reported Depreciation & Amortization (CF) of $392000.0 as of Q3 2025, which was down 7575.76% from $1.7 million recorded in Q2 2025.
  • Zevra Therapeutics' Depreciation & Amortization (CF)'s 5-year high stood at $1.7 million during Q2 2025, with a 5-year trough of $62000.0 in Q3 2023.
  • In the last 5 years, Zevra Therapeutics' Depreciation & Amortization (CF) had a median value of $300000.0 in 2022 and averaged $646736.8.
  • As far as peak fluctuations go, Zevra Therapeutics' Depreciation & Amortization (CF) tumbled by 8442.21% in 2023, and later skyrocketed by 250806.45% in 2024.
  • Quarter analysis of 5 years shows Zevra Therapeutics' Depreciation & Amortization (CF) stood at $64000.0 in 2021, then surged by 368.75% to $300000.0 in 2022, then skyrocketed by 162.33% to $787000.0 in 2023, then skyrocketed by 109.4% to $1.6 million in 2024, then tumbled by 76.21% to $392000.0 in 2025.
  • Its last three reported values are $392000.0 in Q3 2025, $1.7 million for Q2 2025, and $1.6 million during Q1 2025.